Champions Oncology vs Personalis
Personalis is the larger business, with $69.6m of revenue in fiscal 2025 against $59.4m for Champions Oncology (1.2 times as much). Champions Oncology grew faster (4.4% against -17.7%). Champions Oncology kept more of each dollar of sales as profit: a net margin of -2.0% against -116.7%. Champions Oncology carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Champions OncologyCSBR, 2026 | PersonalisPSNL, 2025 |
|---|---|---|
| Revenue | $59.4m | $69.6m |
| Revenue growth | 4.4% | -17.7% |
| Net income | −$1.2m | −$81.3m |
| Operating margin | -1.9% | -126.4% |
| Net margin | -2.0% | -116.7% |
| Return on equity | -30.5% | -35.0% |
| Free cash flow | −$5.0m | −$79.5m |
| Cash | $4.9m | $124m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 214 | 260 |
| Market value | $67.6m | $1.68bn |
| Price vs our value range | — | — |
| Moat score | 63 (Moderate) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 16 sales |